Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 1/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.58 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.57 |
| ▸ | NMBR | P28336 | 2/20 | 0.54 |
| ▸ | GRPR | P30550 | 2/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSH | P09668 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | DPP3 | Q9NY33 | 3/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105546 | 0.95 | CAPN1 (0.58) | NTSR2NTSR1SORT1C5AR1NMBR | |
| SCHEMBL30518080 | 0.93 | NTSR2 (0.65) | NTSR2NTSR1SORT1C5AR1NMBR | |
| SCHEMBL31105525 | 0.90 | C5AR1 (0.58) | NTSR2NTSR1SORT1C5AR1NMBR | |
| SCHEMBL31105542 | 0.89 | NTSR2 (0.64) | NTSR2NTSR1SORT1C5AR1NMBR | |
| SCHEMBL30605453 | 0.86 | NMBR (0.59) | NTSR2NTSR1SORT1C5AR1NMBR | |
| SCHEMBL30974182 | 0.86 | NTSR2 (0.70) | NTSR2NTSR1SORT1C5AR1CAPN1 | |
| SCHEMBL15147203 | 0.86 | F2 (0.60) | C5AR1NMBRGRPRKISS1RCTSL | |
| SCHEMBL30608422 | 0.85 | CTSL (0.55) | NTSR2NTSR1SORT1C5AR1NMBR | |
| SCHEMBL30608996 | 0.85 | CAPN1 (0.58) | NTSR2NTSR1SORT1C5AR1NMBR | |
| SCHEMBL30066910 | 0.84 | CXCR4 (0.58) | NTSR2NTSR1SORT1C5AR1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | WINKEY TECH USA INC (US) | 2026-03-19 | — | — | US | claimed |
| WO-2024217503-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | 深圳市维琪科技股份有限公司 | 2024-10-24 | — | — | WO | claimed |
| CN-116535463-A | Active peptide, composition and use thereof | 深圳市维琪科技股份有限公司 | 2023-08-04 | — | — | CN | claimed |
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | WINKEY TECH USA INC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2024217503-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | 深圳市维琪科技股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-117343140-B | Active peptide, composition and use thereof | 深圳市维琪科技股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-117343140-A | Active peptide, composition and use thereof | 深圳市维琪科技股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116535463-B | Active peptide, composition and use thereof | 深圳市维琪科技股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116535463-A | Active peptide, composition and use thereof | 深圳市维琪科技股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | ARGLU1, ARG1, POT1 | NTSR2 2409/4885NTSR1 1700/4885SORT1 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.